Tag Archive for: Resolution Therapeutics

Weekly roundup: Awards, events, financings and 2 new episodes of Optimum TV

/in

R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease R1 Therapeutics, Inc, a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with kidney disease, announced its launch with an oversubscribed $77.5 million Series A financing, along with the […]

Read more

Weekly roundup: Clearance, Capital & Copenhagen: A week in review!

/in

AMS announced its Interim results for the six months ended 30 June 2025 This week Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announced its unaudited interim results for the six months ended 30 June 2025. Group revenue increased by 63% to £110.8 million and by 66% at constant currency […]

Read more

Weekly roundup: An A* week! Advancements, acquisitions, appointments and Series A financings!

/in ,

AMSilk Secures EUR 52M Strategic Financing to Accelerate Commercial Growth AMSilk GmbH has successfully secured EUR 52 million financing led by existing investor ATHOS (AT Newtec), along with strong participation from fellow existing investors MIG Capital and Novo Holdings. The financing will enable AMSilk to scale industrial production and meet global customer demand for its […]

Read more

Resolution Therapeutics Announces Regenerative Macrophage Therapy (RMT) Manufacturing Process & Candidate Testing Suite at ASGCT 2025

/in

– Proprietary manufacturing process enables robust and scalable GMP-compliant manufacture of autologous engineered RMT products, including lead asset RTX001 in end-stage liver disease (ESLD). – Novel mode of action-based candidate testing suite enabled the discovery of RTX001, which shows enhanced anti-inflammatory and anti-fibrotic effects in vitro and in vivo. – The EMERALD Phase1/2 interventional study […]

Read more

Weekly round-up: How do you turn a 10-person biotech into a $1.1 billion company sale in the space of seven years?

/in

During the BIO-Europe conference in Stockholm, Optimum co-hosted a special reception featuring a fireside chat with Renée Aguiar-Lucander, former CEO of Calliditas, who led the Swedish company since 2017 until recently – taking it from small biotech to its $1.1 billion acquisition. Here, we tell the story of her remarkable seven-year journey with the firm.  Novo […]

Read more